Fungal keratitis

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

Retrieved on: 
Mittwoch, März 15, 2023
Research, Conference, Histoplasma capsulatum, Mortality, Fungal infection, Pseudallescheria boydii, Voriconazole, São Paulo, Amphotericin B, Immunology, USP, Gordon Research Conferences, Biology, Caspofungin, Fungal keratitis, Micafungin, World Health Organization, Fungus, Fluconazole, Cryptococcosis, OTCQB, Posaconazole, News, University, Pharmaceutical industry, Vaccine, Antibiotics, Mucorales

Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.

Key Points: 
  • Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.
  • USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi.
  • Beyond Brilacidin’s broad-spectrum ability to directly inhibit fungal pathogens, Brilacidin may favorably modulate the host response to fungal infections.
  • Corresponding posters for these conferences are available on the Events and Presentations section of the Company’s website at the link below.

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis

Retrieved on: 
Dienstag, Dezember 13, 2022
Eye, Publishing, Posaconazole, Cryptococcus, Mycosis, Voriconazole, Cryptococcosis, Keratitis, Antifungal, Human, Orphan drug, Patient, Toxicity, Mucorales, OTCQB, Research, Mycology, Disease, Fungal keratitis, Caspofungin, University, WHO, Policy, Cornea, World Health Organization, USP, Cryptococcus neoformans, Pharmaceutical industry, Fusarium, Aspergillus

WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing research on the broad-spectrum antifungal activity of Brilacidin, the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.

Key Points: 
  • New in vivo data in an A. fumigatus murine fungal keratitis model showed Brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control.
  • Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight.
  • These new Brilacidin findings in fungal keratitis complement an earlier in vitro and in vivo evaluation of Brilacidin as an ocular anti-infective in bacterial keratitis.
  • A broad-spectrum drug that could target both fungal and bacterial keratitis would be uniquely positioned as to its treatment profile and commercial potential.

Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections

Retrieved on: 
Mittwoch, September 21, 2022
IL, National, HX-21, Safety, Fungal keratitis, Lasers in Medical Science, Legislation, Bascom, Hematology, Physician, Percussion section, NIH, HX, Time, U.S. News & World Report, Glaucoma, Neuro-ophthalmology, Company, Riboflavin, UM, Degenerative disease, No, Cornea, Staphylococcus, Adriana Arboleda, Doctor of Philosophy, SEC, Veni, vidi, vici, Methicillin-resistant Staphylococcus aureus, PDAT, Retina, University, Review, MD, OTCQB, Health, Surgical Outcomes Analysis and Research, Forward-looking statement, Severe cognitive impairment, Pseudomonas aeruginosa, Patient, GLOBE, Drug discovery, Department, OBC, Immunotherapy, Cataract, Dermatology, Eye, P.O, Quality of life, Bascom Palmer Eye Institute, Laser, Rose bengal, Infection, Staphylococcus aureus, Pharmaceutical industry, Antibiotics, Copper, Ophthalmology, U.S

The Company also initiated a sponsored research program with OBC to investigate Provectus rose bengal for the treatment of infectious keratitis.

Key Points: 
  • The Company also initiated a sponsored research program with OBC to investigate Provectus rose bengal for the treatment of infectious keratitis.
  • BPEI serves as the Department of Ophthalmology for the UM Miller School of Medicine in Miami, Florida.
  • Its mission is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research.
  • 1 ranking since U.S. News began surveying American physicians for its annual Best Hospitals rankings 33 years ago.

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM

Retrieved on: 
Dienstag, Juni 7, 2022
Severe cognitive impairment, Marketing, Leadership, Eye, Company, Acanthamoeba keratitis, Research, EMA, EC, UCL Institute of Ophthalmology, Standard of care, Transplant, University College London, Disease, CEO, Committee, European Directive on Traditional Herbal Medicinal Products, Partnership, Trophozoite, CHMP, Medicines and Healthcare products Regulatory Agency, Patient, Fungal keratitis, SIFI, EAPS, Committee for Medicinal Products for Human Use, Polyhexanide, Phase, Medication, Incidence, Quality of life, European Medicines Agency, Royal commission, European Commission, Drug development, West Pharmaceutical Services, Marketing Authorisation Application, Institute, AK, Cyst, Medical device, Pharmaceutical industry, Acanthamoeba, Ophthalmology

"We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.

Key Points: 
  • "We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.
  • "We look forward to helping facilitate broader access to polihexanide for patients with critical unmet medical needs suffering from acanthamoeba keratitis."
  • AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM

Retrieved on: 
Dienstag, Juni 7, 2022
Severe cognitive impairment, Marketing, Leadership, Eye, Company, Acanthamoeba keratitis, Research, EMA, EC, UCL Institute of Ophthalmology, Standard of care, Transplant, University College London, Disease, CEO, Committee, European Directive on Traditional Herbal Medicinal Products, Partnership, Trophozoite, CHMP, Medicines and Healthcare products Regulatory Agency, Patient, Fungal keratitis, SIFI, EAPS, Committee for Medicinal Products for Human Use, Polyhexanide, Phase, Medication, Incidence, Quality of life, European Medicines Agency, Royal commission, European Commission, Drug development, West Pharmaceutical Services, Marketing Authorisation Application, Institute, AK, Cyst, Medical device, Pharmaceutical industry, Acanthamoeba, Ophthalmology

"We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.

Key Points: 
  • "We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.
  • "We look forward to helping facilitate broader access to polihexanide for patients with critical unmet medical needs suffering from acanthamoeba keratitis."
  • AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.

SIFI RECEIVES FAVORABLE FEEDBACK FROM THE US FDA ON AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS

Retrieved on: 
Montag, Mai 16, 2022
Company, Disease, Polyhexanide, Acanthamoeba keratitis, Eye, Incidence, NCE, Cyst, Patient, Quality of life, Severe cognitive impairment, SIFI, Research, Patent, FDA, Trophozoite, Massachusetts Eye and Ear, Transplant, University, Orphan, NDA, American Journal, Illinois Eye and Ear Infirmary, AK, The Company, Ophthalmology, MD, Fungal keratitis, CEO, Pharmaceutical industry, Acanthamoeba, New chemical entity

ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.

Key Points: 
  • ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.
  • ABOUT Acanthamoeba Keratitis (AK): AK is a rare, acute, severe parasitic corneal infection caused by Acanthamoeba, a free-living amoeba.
  • ABOUT SIFI: SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935.

SIFI RECEIVES FAVORABLE FEEDBACK FROM THE US FDA ON AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS

Retrieved on: 
Montag, Mai 16, 2022
Company, Disease, Polyhexanide, Acanthamoeba keratitis, Eye, Incidence, NCE, Cyst, Patient, Quality of life, Severe cognitive impairment, SIFI, Research, Patent, FDA, Trophozoite, Massachusetts Eye and Ear, Transplant, University, Orphan, NDA, American Journal, Illinois Eye and Ear Infirmary, AK, The Company, Ophthalmology, MD, Fungal keratitis, CEO, Pharmaceutical industry, Acanthamoeba, New chemical entity

ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.

Key Points: 
  • ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.
  • ABOUT Acanthamoeba Keratitis (AK): AK is a rare, acute, severe parasitic corneal infection caused by Acanthamoeba, a free-living amoeba.
  • ABOUT SIFI: SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935.

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

Retrieved on: 
Montag, März 14, 2022
University, Acanthamoeba keratitis, Incidence, Fungal keratitis, Mazzone, Business, Risk, Company, III, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Person, EMA, Severe cognitive impairment, DNA, PDUFA, Patient, Marketing, European Medicines Agency, SIFI, Infection, Disease, Food, ODD, Program, Diagnosis, Pharmaceutical industry, Ophthalmology, Lancet

According to The Lancet , annual global incidence of fungal keratitis is estimated at 1,051,787 cases, with the highest rates in Asia and Latin America.

Key Points: 
  • According to The Lancet , annual global incidence of fungal keratitis is estimated at 1,051,787 cases, with the highest rates in Asia and Latin America.
  • In the U.S., an estimated 15,660 patients annually most of whom are contact lens wearers or agricultural workers are diagnosed with fungal keratitis.
  • Only one drug is currently approved for fungal keratitis in the U.S., and around one in three patients fail on the treatment.
  • Brown L., Leck AK, Gichangi M, Burton MJ, Denning DW, The global incidence and diagnosis of fungal keratitis.

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

Retrieved on: 
Montag, März 14, 2022
University, Acanthamoeba keratitis, Incidence, Fungal keratitis, Mazzone, Business, Risk, Company, III, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Person, EMA, Severe cognitive impairment, DNA, PDUFA, Patient, Marketing, European Medicines Agency, SIFI, Infection, Disease, Food, ODD, Program, Diagnosis, Vaccine, Pharmaceutical industry, Ophthalmology, Lancet

CATANIA, Italy, March 14, 2022 /PRNewswire/ -- SIFI S.p.A. ("SIFI" or the "Company"), a leading international ophthalmic pharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") has approved the company's Orphan Drug Designation ("ODD") application for its investigational anti-infective polymer polihexanide for the treatment of fungal keratitis. This is a second orphan ophthalmic indication for the polihexanide Research & Development program. 

Key Points: 
  • CATANIA, Italy, March 14, 2022 /PRNewswire/ -- SIFI S.p.A. ("SIFI" or the "Company"), a leading international ophthalmic pharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") has approved the company's Orphan Drug Designation ("ODD") application for its investigational anti-infective polymer polihexanide for the treatment of fungal keratitis.
  • This is a second orphan ophthalmic indication for the polihexanide Research & Development program.
  • Only one drug is currently approved for fungal keratitis in the U.S., and around one in three patients fail on the treatment.
  • Brown L., Leck AK, Gichangi M, Burton MJ, Denning DW, The global incidence and diagnosis of fungal keratitis.

Global Artificial Cornea and Corneal Implant Market (2021 to 2028) - by Type, Transplant Type, Disease Indication, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, November 4, 2021
Biotechnology, Optical, Health, Surgery, Cornea, Fungal keratitis, Directorate General of Health Services, Industry, National Center for Biotechnology Information, Keratoprosthesis, 3D ultrasound, Eye, CAGR, Keratoconus, Growth, COVID-19, Health care, American Academy, Transplant, Hospital, Fuchs, National Center for Health Research, Fuchs' dystrophy, Time, Directorate, Prevalence, Patient, Medical device, Health insurance, Marketing

The artificial cornea and corneal implant market, by type, is segmented into human cornea and artificial cornea.

Key Points: 
  • The artificial cornea and corneal implant market, by type, is segmented into human cornea and artificial cornea.
  • Based on transplant type, the artificial cornea and corneal implant market is segmented into penetrating keratoplasty, endothelial keratoplasty, and others.
  • The artificial cornea and corneal implant market, based on disease indication, is segmented into Fuchs' Dystrophy, keratoconus, fungal keratitis, and others.
  • Based on end user, the artificial cornea and corneal implant market is segmented into hospitals, specialty clinics and ASCs, and others.